Alnylam Pharmaceuticals shares rose 10% Friday after the company nabbed FDA approval to sell its drug Amvuttra to a larger population of patients with a genetic heart condition.
The FDA cleared the drug after the close on Thursday, allowing Alnylam to compete against Pfizer and BridgeBio to treat patients with the disease. Amvuttra sales are expected to top $1 billion next year, and reach $5.8 billion in 2030, according to analysts polled by FactSet.
Alnylam has long been a favorite among biotech investors, but the company hasn't yet shown it can transition from being a R&D innovator to a sustainable business. "We really are within touching distance of achieving sustainable profitability," said Chief Executive Yvonne Greenstreet in an interview. "Particularly in the current ecosystem, we feel that we're in rarefied air."
This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).
(END) Dow Jones Newswires
March 21, 2025 13:21 ET (17:21 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。